In defining the biological effects ofthe 10 B (n,α) 7 Li neutron capturereaction, we have proposeda deterministic parsing model (ISHIYAMA-IMAHORI model) to determine the Compound Biological Effectiveness (CBE) factor in Borono-Phenyl-Alanine (BPA)-mediated Boron Neutron Capture Therapy (BNCT). In present paper, we the case of application to actual patient data, which is founded on this model for tissuesandtumor.
Where, A, a and t 0 are constants . In Japan, implemented deployment of accelerator-driven neutron source for Boron Neutron Capture Therapy (BNCT) is accomplished in 2014 in National Cancer Center, of which system was designed with the production of neutrons via threshold 7 Li (p, n) 7 Be reaction at 25kW proton beam with energy of 2.5
MeV, which was designed to dovetail the narrow peak band resonance of lithium target and started its installation at middle of 2013. This BNCT device is expected to offer the potential for achieving the objects of which any treatment capable of sterilizing the primary tumor locally will result in a high probability of cure.
BNCT is a targeted radio-therapeutic modality used for the treatment of brain tumors and melanoma and a bimodal approach to cancer therapy. Before BNCT, Boron-10( 10 B)-enriched compounds are used to deliver 10 B to tumors. Once tumor uptake of a given boron delivery agent relative to the surrounding normal tissues and blood has been maximized and then irradiation with low-energy neutron takes place. An alternative boron delivery agent, p-borononphenylalaine (BPA) instead of administration of the boron delivery agent borocaptate sodium (BSH), is being used Li neutron capture reaction relative to photons, the term compound biological effectiveness (CBE) factor was used as an alternative to RBE. Calculation of the CBE factor is similar to that of the RBE factor [9] . Equating the X-ray ED 50 dose with a BNC dose (beam + BSH) that gives the same end point of a 50% incident of ulceration produces the following equation:
The The CBE factors concerning to tumor, skin lung, liver [10] [11], heart [12] and oral mucosal tissues [13] were reported and prospect of actually using BNCT for the patients has been developing under the right circumstances. However, there is no theoretical unified explanation of the CBE factors for normal tissues and tumor, despite significance of high precision of the CBE factor evaluation is requested for the patients.
Recently, the authors proposed deterministic parsing model of CBE factors (ISHIYAMA-IMAHORI model) and applied to human tumor brain cases and derived good results dovetailed with empirical facts [14] [15] .
The purpose of the present investigation was to demonstrate the unified methodology for the evaluation of the CBE factors for normal tissues and tumor in BNCT.
II. Materials and Methods

a)
B concentration measurement of BPA by dynamic PET technique
A brain tumor patient (grade IV) was given low dose (approximately~100μg/g) of intravenous radioactively-labeled 18 F-BPA before BNCT and diagnosed cancer by Positron-Emission-Tomography (PET) [16] . To obtain 10 B concentration in a body, (2) and this is because that we chose drip injection in present study. From these results, it is clear that very good data fitting curves of the logistic function to dynamic PET data were observed and each constant in eq. (1) are obtained in the tumor and normal tissue. These results are listed in the table (Table 1) . (1), we defined N th and N max as follows: 
(2) for tumor and normal tissue c) Application of the calculation method and its clinical significance
The charm of the BNCT treatment is that again and again for the same patients and their affected area is capable of irradiation treatment. Therefore, the cure of intractable cancer in a short time by BNCT treatment is not a dream. However, BNCT treatment at this stage is time-consuming due to the following reasons. Normally, cancer patients are given low doses of intravenous radioactively-labelled 18F-BPA before BNCT and diagnosed cancer by PositronEmission-Tomography (PET). Physicians developed a treatment plan by BNCT based on PET diagnosis and then after administrates high dose of BPA to the patients.
So practical value of present research is that the diagnosis and treatment cycle can be achieved at the same time shorten with high accuracy.
Present research results, ie by 18F-BPA drip injection administration and dynamic PET measurement method, ISHIYAMA-IMAHORI model immediately provides a high-precision CBE factor and BNCT treatment for a kind of cancer and its severity in patients individual.
IV. Conclusions
ISHIYAMA
-IMAHORI model below immediately provides a high-precision CBE factor and BNCT treatment for a kind of cancer and its severity in patients individual by 18F-BPA drip injection administration and dynamic PET measurement method 
